Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- HIV / AIDs
- Disease
- Therapeutic
- Immune
- Vaccine
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 233457
With this amendment, the HBV License now reads as follows for the LdT License
– Subject to the terms and conditions of this Agreement, Licensor grants to The Swiss Licensee a right and license, with the right to grant sublicenses as permitted, under Licensors rights in the Licensors Intellectual Property and in the Joint Intellectual Property to manufacture, have made, use, market and promote, import and export, offer for sale, sell and distribute the LdT Product in the Field within the Licensees Territory during the applicable Country Terms for the LdT Product. The license granted to Licensee in this subsection shall be exclusive, even with respect to Licensor as to the Licensees Territory.
With this amendment, EU Countries and Licensee takes over control of Development, Manufacture and Commercialization worldwide, and books sales.
– Licensee will pay royalties for the US Territory, the Major EU Countries and the Rest of World Territory.
– the Parties will terminate the existing Supply Agreement and the Commercial Manufacturing Agreement, along with some changes to other agreements.
– Licensor grants to Licensee a license to Manufacture worldwide.
This agreement has pediatric exclusivity terms and a non-exclusive grant back to Licensor.
The patents cover
– Methods of Treating Hepatitis Delta Virus Infection with Beta-L-2- Deoxynucleosides
– Crystalline and Amorphous Forms of B-L-2-Deoxythymidine
– B-L-2-Deoxynucleosides for the Treatment of Lamivudine-Resistant
– Industrially Scalable Nucleoside Synthesis
– Synthesis of Beta-L-2- Deoxynucleosides
– B-L-2-Deoxypyrimidine Nucleosides for the Treatment of Hepatitis B, and,
– Methods of Manufacture of 2-Deoxy-B-L-Nucleosides
IPSCIO Record ID: 257474
The parties wish to further amend the Agreement to provide that Merck shall have rights to vaccine products for the treatment of patients infected with Human Immunodeficiency Virus and Hepatitis B Virus.
IPSCIO Record ID: 3782
The intellectual property was taken from the University and includes possible treatments for herpes, HIV, and other viruses. The University sued the company who was gaining from the patents, asserting that a former professor had founded the Licensee company and made off with University intellectual property. The settlement applies to worldwide sales of telbivudine, an antiviral drug used to treat Hepatitis B.
IPSCIO Record ID: 362455
Licensed Products means a product containing P-VL-FD4C that is developed, made, used, marketed, imported, Sold, or offered for Sale by Licensee, its Affiliates or any Sublicensees in any country of the Territory where the University owns or controls at least one Valid Claim covering the Subject Technology.
University Subject Technology shall mean all technology, trade secrets, know-how, methods of treatment, documents, materials, tests, all improvements thereto, and all proprietary information pertaining to the compound B-L-FD4C (2 ,3-dideoxy-2 ,3 -didehydro-B-L-5-fluorocytidine) or any 5- or N4 derivatives or products thereof.
IPSCIO Record ID: 362454
Licensor hereby grants to Licensee a non-transferable, worldwide, exclusive license under the Licensed Technology to make, have made, import, export, use, sell and have sold Licensed Products and practice the Inventions.
The patents include
Novel L-23-Dideoxy Nucleoside Analogs as Anti-Hepatitis (HBV) Agents;
Reduced Toxicity Compositions and Methods for Treating HIV Infections; and,
Process for High Yield Diastereoselective Syntheses of Dideoxvnucleotides.
